Form 4: Heron Therapeutics Executive Acquires Shares

Heron Therapeutics EVP, CFO Ira Duarte acquired 3,874 shares of common stock through the vesting of restricted stock units.

Summary

• Ira Duarte, EVP and Chief Financial Officer of Heron Therapeutics, Inc., acquired 3,874 shares of common stock on April 19, 2026.
• The acquisition was a result of the vesting of restricted stock units.
• Following this transaction, Mr. Duarte beneficially owns 215,876 shares of common stock directly.
• Additionally, 27,120 restricted stock units were acquired, which vest in 16 equal quarterly installments starting from January 19, 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a standard insider transaction related to executive compensation rather than a significant new investment or divestment.

Positives

• Executive leadership is acquiring company stock, which can signal confidence in the company's future prospects.
• The acquisition of 3,874 shares by the CFO increases his direct beneficial ownership.

Future Outlook

The vesting of restricted stock units suggests ongoing compensation and incentive structures for management, implying a continued focus on performance and alignment with shareholder interests.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, particularly by CFOs, are often viewed positively by the market as they can indicate management's belief in the company's intrinsic value and future growth potential. This aligns with typical executive compensation strategies in the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: May view the CFO's acquisition of stock positively, signaling confidence in the company's future performance.
• Employees: The vesting of restricted stock units is part of the employee compensation structure, reinforcing alignment with company goals.
• Management: The transaction reflects the execution of existing compensation plans.

Next Steps

• Continued vesting of restricted stock units over the next several quarters.
• Ongoing reporting of beneficial ownership changes as required by SEC regulations.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, CFO, Executive Compensation